CompletedPhase 2NCT01736683
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Studying Chronic myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Rodrigo Ito, MDCelgene Corporation
- Intervention
- Sotatercept(drug)
- Enrollment
- 74 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2018
Study locations (20)
- Rocky Mountain Cancer Center-Midtown, Denver, Colorado, United States
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Johns Hopkins, Baltimore, Maryland, United States
- Dana-Farber / Harvard Cancer Institute, Boston, Massachusetts, United States
- Monter Cancer Center, North Shore LIJ Health Systems, Lake Success, New York, United States
- Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York, United States
- The Cleveland Clinic Foundation Hematology and Medical Oncology Rm 35, Cleveland, Ohio, United States
- Sarah Cannon Research Inst, Nashville, Tennessee, United States
- Texas Oncology Round Rock Cancer Center - Round Rock, Round Rock, Texas, United States
- University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
- Texas Oncology, P.A. - Tyler, Tyler, Texas, United States
- Virginia Oncology Associates, Norfolk, Virginia, United States
- Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States
- Centre Hospitalier Universitaire d'Avicennes, Bobigny, France
- Institute Paoli-Calmettes Service Haematology, BP 156,, France
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01736683 on ClinicalTrials.govOther trials for Chronic myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07071155Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT07512882Cohort of Patients With Chronic Myelomonocytic LeukemiaGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGPHASE2NCT06815003Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningCity of Hope Medical Center
- RECRUITINGPHASE2NCT06597734A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative NeoplasmM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06543381Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantCity of Hope Medical Center
- RECRUITINGPHASE3NCT06647862IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- RECRUITINGPHASE1, PHASE2NCT06159491Pacritinib in CMMLDouglas Tremblay
- RECRUITINGPHASE1NCT06218628Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionFox Chase Cancer Center